Protective Effects of Kampo Medicines and Baicalin against Intestinal Toxicity of a New Anticancer Camptothecin Derivative, Irinotecan Hydrochloride (CPT-11), in Rats

Access this Article

Search this Article

Author(s)

    • KASAI Yoshio
    • Drug Safety Research Center, Developmental Research Lavoratories
    • KITANO Yutaka
    • Drug Safety Research Center, Developmental Research Lavoratories
    • MORI Kazuhiko
    • Drug Safety Research Center, Developmental Research Lavoratories, Daiichi Pharmaceutical Co., Ltd.
    • KOBAYASHI Reiko
    • Drug Safety Research Center, Developmental Research Lavoratories, Daiichi Pharmaceutical Co., Ltd.
    • HAGIWARA Takehiro
    • Drug Safety Research Center, Developmental Research Lavoratories, Daiichi Pharmaceutical Co., Ltd.
    • KAKIHATA Kohji
    • Drug Safety Research Center, Developmental Research Lavoratories, Daiichi Pharmaceutical Co., Ltd.
    • HIROHASHI Masaaki
    • Drug Safety Research Center, Developmental Research Lavoratories, Daiichi Pharmaceutical Co., Ltd.
    • NOMURA Mamoru
    • Drug Safety Research Center, Developmental Research Lavoratories, Daiichi Pharmaceutical Co., Ltd.
    • NAGAI Eiichi
    • Medical Product Management and Market Planning, Daiichi Pharmaceutical Co., Ltd.
    • KAMATAKI Tetsuya
    • Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Hokkaido University

Journal

  • Jpn J Cancer Res

    Jpn J Cancer Res 86(10), 978-984, 1995-10-31

References:  24

Cited by:  14

Codes

Page Top